BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22156347)

  • 1. Trogocytosis is a gateway to characterize functional diversity in melanoma-specific CD8+ T cell clones.
    Uzana R; Eisenberg G; Sagi Y; Frankenburg S; Merims S; Amariglio N; Yefenof E; Peretz T; Machlenkin A; Lotem M
    J Immunol; 2012 Jan; 188(2):632-40. PubMed ID: 22156347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers.
    Yee C; Savage PA; Lee PP; Davis MM; Greenberg PD
    J Immunol; 1999 Feb; 162(4):2227-34. PubMed ID: 9973498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigen-specific transfer of functional programmed death ligand 1 from human APCs onto CD8+ T cells via trogocytosis.
    Gary R; Voelkl S; Palmisano R; Ullrich E; Bosch JJ; Mackensen A
    J Immunol; 2012 Jan; 188(2):744-52. PubMed ID: 22174448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diversity of the cytotoxic melanoma-specific immune response: some CTL clones recognize autologous fresh tumor cells and not tumor cell lines.
    Dufour E; Carcelain G; Gaudin C; Flament C; Avril MF; Faure F
    J Immunol; 1997 Apr; 158(8):3787-95. PubMed ID: 9103444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity.
    Clay TM; Custer MC; Sachs J; Hwu P; Rosenberg SA; Nishimura MI
    J Immunol; 1999 Jul; 163(1):507-13. PubMed ID: 10384155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective expansion of a specific anti-tumor CD8+ cytotoxic T lymphocyte clone in the bulk culture of tumor-infiltrating lymphocytes from a melanoma patient: cytotoxic activity and T cell receptor gene rearrangements.
    Gervois N; Heuze F; Diez E; Jotereau F
    Eur J Immunol; 1990 Apr; 20(4):825-31. PubMed ID: 1971794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presentation of acquired peptide-MHC class II ligands by CD4+ regulatory T cells or helper cells differentially regulates antigen-specific CD4+ T cell response.
    Zhou G; Ding ZC; Fu J; Levitsky HI
    J Immunol; 2011 Feb; 186(4):2148-55. PubMed ID: 21242518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition.
    Moore TV; Lyons GE; Brasic N; Roszkowski JJ; Voelkl S; Mackensen A; Kast WM; Le Poole IC; Nishimura MI
    Cancer Immunol Immunother; 2009 May; 58(5):719-28. PubMed ID: 18836717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes.
    Maeurer MJ; Chan HW; Karbach J; Salter RD; Knuth A; Lotze MT; Storkus WJ
    Eur J Immunol; 1996 Nov; 26(11):2613-23. PubMed ID: 8921947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigen specific and MHC nonrestricted cytotoxicity of T cell receptor alpha beta+ and gamma delta+ human T cell clones isolated in IL-4.
    Paliard X; Yssel H; Blanchard D; Waitz JA; deVries JE; Spits H
    J Immunol; 1989 Jul; 143(2):452-7. PubMed ID: 2472439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for involvement of the gamma, delta T cell antigen receptor in cytotoxicity mediated by human alloantigen-specific T cell clones.
    Rivas A; Koide J; Cleary ML; Engleman EG
    J Immunol; 1989 Mar; 142(6):1840-6. PubMed ID: 2466078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defective lymphokine production by most CD8+ and CD4+ tumor-specific T cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumor cells in vitro.
    Guilloux Y; Viret C; Gervois N; Le Dréan E; Pandolfino MC; Diez E; Jotereau F
    Eur J Immunol; 1994 Sep; 24(9):1966-73. PubMed ID: 7522155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells. Analysis of specificity and mechanisms of interaction.
    Anichini A; Mazzocchi A; Fossati G; Parmiani G
    J Immunol; 1989 May; 142(10):3692-701. PubMed ID: 2469723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specificity, T cell receptor diversity and activation requirements of CD4+ and CD8+ clones derived from human melanoma-infiltrating lymphocytes.
    Pandolfino MC; Viret C; Gervois N; Guilloux Y; Davodeau F; Diez E; Jotereau F
    Eur J Immunol; 1992 Jul; 22(7):1795-802. PubMed ID: 1623924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo.
    Prévost-Blondel A; Zimmermann C; Stemmer C; Kulmburg P; Rosenthal FM; Pircher H
    J Immunol; 1998 Sep; 161(5):2187-94. PubMed ID: 9725210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic activity and lymphokine production of T cell receptor (TCR)-alpha beta+ and TCR-gamma delta+ cytotoxic T lymphocyte (CTL) clones recognizing HLA-A2 and HLA-A2 mutants. Recognition of TCR-gamma delta+ CTL clones is affected by mutations at positions 152 and 156.
    Spits H; Paliard X; Engelhard VH; de Vries JE
    J Immunol; 1990 Jun; 144(11):4156-62. PubMed ID: 2111341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
    Rivoltini L; Kawakami Y; Sakaguchi K; Southwood S; Sette A; Robbins PF; Marincola FM; Salgaller ML; Yannelli JR; Appella E
    J Immunol; 1995 Mar; 154(5):2257-65. PubMed ID: 7868898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent occurrence of high affinity T cells against MELOE-1 makes this antigen an attractive target for melanoma immunotherapy.
    Godet Y; Desfrançois J; Vignard V; Schadendorf D; Khammari A; Dreno B; Jotereau F; Labarrière N
    Eur J Immunol; 2010 Jun; 40(6):1786-94. PubMed ID: 20217862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Large and dissimilar repertoire of Melan-A/MART-1-specific CTL in metastatic lesions and blood of a melanoma patient.
    Mandruzzato S; Rossi E; Bernardi F; Tosello V; Macino B; Basso G; Chiarion-Sileni V; Rossi CR; Montesco C; Zanovello P
    J Immunol; 2002 Oct; 169(7):4017-24. PubMed ID: 12244204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Partial purification of murine tumor-associated peptide epitopes common to histologically distinct tumors, melanoma and sarcoma, that are presented by H-2Kb molecules and recognized by CD8+ tumor-infiltrating lymphocytes.
    Itoh T; Storkus WJ; Gorelik E; Lotze MT
    J Immunol; 1994 Aug; 153(3):1202-15. PubMed ID: 7517974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.